Stock Screener App

Gratuito -

Installare

64.01

1.30% 0.82

after-market

Dopo l'orario di chiusura: 64.76 0.75 +1.17%

Cytokinetics Inc (CYTK)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché CYTK Giù? Forum Previsione Frazionamento azionario

Cytokinetics Inc Borsa (CYTK) Ultime notizie

Assessing Whether Cytokinetics (CYTK) Looks Undervalued After Recent Share Price Momentum - Yahoo Finance

How MYQORZO’s REMS‑Restricted U.S. Launch Will Impact Cytokinetics (CYTK) Investors - Yahoo Finance

Cytokinetics launches first product, Myqorzo - The Pharma Letter

Analyst Upgrade: What is the long term forecast for Cytokinetics Incorporated stock2025 Price Momentum & Community Consensus Trade Signals - baoquankhu1.vn

Cytokinetics (CYTK) Launches HCM Awareness Campaign with Olympic Star - GuruFocus

CYTK: Cytokinetics Launches Myqorzo in the U.S. for Heart Condition - GuruFocus

Olympian Sydney McLaughlin-Levrone on hypertrophic cardiomyopathy at home - Stock Titan

Cytokinetics Announces U.S. Launch of MYQORZO™ (aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy - Quiver Quantitative

New heart drug MYQORZO reaches U.S. patients, but with strict safety rules - Stock Titan

US FDA caps 2025 with December high of 27 drug approvals - BioWorld MedTech

Cytokinetics, Incorporated (CYTK) Stock Analysis: Uncovering a 41% Potential Upside in the Biotech Sector - directorstalkinterviews.com

RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $95 - 富途资讯

Cytokinetics Board Faces Claims of Breach of Fiduciary Duty as Stock Plummets - Intellectia AI

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect - ACCESS Newswire

The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors - marketscreener.com

Bull Bear: What are HSPOs earnings expectationsLayoff News & Capital Efficiency Focused Strategies - baoquankhu1.vn

RBC Capital Reiterates Outperform Rating for Cytokinetics (CYTK) - GuruFocus

Key facts: B. Riley Raises Cytokinetics Price Target to $108; Stock Options Issued - TradingView

Cytokinetics (CYTK) Sees Positive Analyst Rating Updates: Price Target Raised | CYTK Stock News - GuruFocus

Royal Bank Of Canada Reiterates "Outperform" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat

Brokers Issue Forecasts for Cytokinetics FY2026 Earnings - MarketBeat

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Cytokinetics announces inducement grants under Nasdaq Listing Rule - marketscreener.com

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule - TradingView

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Cytokinetics (NASDAQ:CYTK) Given New $74.00 Price Target at JPMorgan Chase & Co. - MarketBeat

CYTK: JP Morgan Raises Price Target, Maintains Overweight Rating - GuruFocus

What makes Cytokinetics Incorporated stock attractive to growth fundsMarket Activity Report & Community Trade Idea Sharing - bollywoodhelpline.com

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire about Securities Investigation - ACCESS Newswire

Gainers Report: Can Cytokinetics Incorporated reach all time highs this year - baoquankhu1.vn

Should you avoid Cytokinetics Incorporated stock right now2025 Risk Factors & Stepwise Trade Signal Guides - baoquankhu1.vn

Profit Recap: Is TCBX in accumulation or distribution phaseWeekly Market Summary & Safe Swing Trade Setup Alerts - baoquankhu1.vn

Spinal Muscular Atrophy Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme - Barchart.com

Orsini Selected as Specialty Pharmacy Partner for Cytokinetics's MYQORZO™ (aficamten) - PR Newswire

SG Americas Securities LLC Purchases 43,349 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat

Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech With 41% Upside Potential - DirectorsTalk Interviews

Cytokinetics, Incorporated (NASDAQ:CYTK) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

FDA approves seven NMEs in December - biocentury.com

Jefferies raises Cytokinetics stock price target to $90 on ACACIA study - Investing.com Canada

How Cytokinetics Incorporated stock trades before earnings2025 Volume Leaders & Momentum Based Trading Ideas - ulpravda.ru

Is Cytokinetics Incorporated stock attractive for long term wealth building2025 Institutional Moves & High Accuracy Trade Alerts - ulpravda.ru

Is Cytokinetics Incorporated stock attractive for hedge fundsQuarterly Portfolio Summary & Safe Entry Trade Reports - ulpravda.ru

Is Cytokinetics Incorporated stock a good choice for value investorsWeekly Investment Report & Step-by-Step Swing Trade Plans - ulpravda.ru

Is Cytokinetics Incorporated (KK3A) stock a top pick for value investorsQuarterly Trade Summary & Daily Growth Stock Investment Tips - ulpravda.ru

Can Cytokinetics Incorporated stock deliver consistent earnings growthPortfolio Value Summary & Risk Controlled Stock Alerts - ulpravda.ru

Risk Analysis: Can Cytokinetics Incorporated stock reach $100 price targetMarket Performance Recap & Expert Curated Trade Ideas - ulpravda.ru

Can Cytokinetics Incorporated stock maintain growth trajectoryInsider Selling & Daily Profit Focused Screening - ulpravda.ru

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore ... - bdtonline.com

Important Notice to Long-Term Shareholders of Cytokinetics, - GlobeNewswire

Press Telegram - FinancialContent

How Aficamten REMS Disclosure Probe Will Impact Cytokinetics (CYTK) Investors - Yahoo Finance

HC Wainwright & Co. maintains Cytokinetics (CYTK) buy recommendation - MSN

Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, ... - Bluefield Daily Telegraph

Notice to Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire

Insider Sell: Andrew Callos Sells 15,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus

Cytokinetics (NASDAQ:CYTK) EVP Sells $904,200.00 in Stock - MarketBeat

Cytokinetics Executive Sells 15,000 Shares - TradingView — Track All Markets

Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times

Tango Therapeutics Appoints Sung Lee to Board of Directors - GlobeNewswire Inc.

Callos, Cytokinetics EVP, sells $112,584 in stock By Investing.com - Investing.com Nigeria

Cytokinetics (NASDAQ:CYTK) EVP Sells $112,590.76 in Stock - MarketBeat

Callos, Cytokinetics EVP, sells $112,584 in stock - Investing.com India

RVMD

$99.82

2.09%

INCY

$103.47

0.87%

GMAB

$34.40

2.78%

BNTX

$119.34

1.14%

INSM

$162.64

1.83%

ONC

$336.16

0.48%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters